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Abstract
This review addresses genes differentially expressed in the
mammary gland transcriptome during the progression of mammary
carcinogenesis in BALB/c mice that are transgenic for the rat neu
(ERBB2, or HER-2/neu) oncogene (BALB-neuT664V-E mice). The
Ingenuity knowledge database was used to characterize four
functional association networks whose hub genes are directly
linked to inflammation (specifically, the genes encoding IL-1β,
tumour necrosis factor, interferon-γ, and monocyte chemoattractant
protein-1/CC chemokine ligand-2) and are increasingly expressed
during such progression. In silico meta-analysis in a human breast
cancer dataset suggests that proinflammatory activation in the
mammary glands of these mice reflects a general pattern of human
breast cancer.
Introduction
Inflammation, the archetypal response to invasion, has
evolved as a local protective response to life-threatening
invasion; it is required to be rapid and devastating, sometimes
regardless of the cost to the host. When viewed in the light of
evolutionary pressure, the frequently disastrous long-term
consequences of inflammation are a small price to pay for the
protection against the immediate danger avoided.
It is now clear, however, that various distinct reactions are
encompassed within the term ‘inflammation’. Development of
the immune system has led to sophisticated decoding of
danger signals elicited by incursion of foreign bodies, and
retaliatory responses are adjusted accordingly. The type of
cells recruited, their state of activation, the reactive
substances that they release, their guidance by cytokines and
soluble factors, and the time frame over which the reaction
occurs will all depend on both the type of signals and the
ability of the invader to resist responses. Therefore, it is hardly
surprising that some of the molecular mechanisms that
sustain flares of inflammation may have opposing effects on
the progression of early neoplastic lesions [1].
Acute inflammation cures lethal tumours
Acute inflammation can certainly destroy both initial and
established neoplastic lesions. Indeed, much of our current
understanding of tumour immunology can be traced back to
Cooley’s observations of the ability of the acute inflammation
elicited by bacterial infections to cure human carcinomas [2].
Similar observations have also been reported in countless
studies of experimental tumours. However, it has also been
shown that tumours can be destroyed by a more focused
assault triggered by double-strand polynucleotides [3] and
unmethylated-CpG oligodesoxynucleotides [4]. Moreover,
because cytokines guide inflammatory reactions, most can
initiate and guide inflammatory patterns that have a distinct
ability to inhibit tumour growth. The powerful anti-tumour
activity of tumour necrosis factor (TNF)-α driven inflammation,
for instance, is accompanied by dramatic adverse effects that
confine its therapeutic use to isolated tissue perfusion [5].
IL-2 also recruits natural immunity mechanisms that exhibit
marked anti-tumour activity in patients with advanced cancer
[6]. Administration of minute amounts of IL-2 at the tumour
site induces neutrophil infiltration, which produces dramatic,
albeit temporary, regression [7].
Several lines of experimental data have shown that tumour
cells engineered to release a cytokine trigger a strong
inflammatory reaction, which results in acute tumour destruc-
tion and induction of tumour-specific immune memory [8].
Systematic investigation of the reaction elicited by a mouse
mammary adenocarcinoma cell line (TSA) transfected with
several cytokine genes has shown that the cytokines produced
induce distinct local inflammatory reactions. Neutrophils are
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the dominant infiltrating cells recruited by TSA-IL-2 cells (TSA
cells transfected with the gene encoding IL-2) [9],
eosinophils by TSA-IL-4 and TSA-IL-5 cells [10,11], natural
killer cells by TSA-IL-12 cells [12], and macrophages by TSA-
IFN-γ cells [10]. Other cytokines such as IL-7 [13], TNF-α
[13] and IFN-α [14], or chemokines such as CC chemokine
ligand (CCL)16 (liver expressed chemokine [LEC]) [15]
activate acute inflammatory reactions and recruit mixed
leucocyte populations. Although reactions elicited by
cytokines are markedly different histologically, those elicited
by TSA tumour cells engineered to release IL-2, IL-4, IL-7,
IL-12, TNF-α, IFN-γ and LEC/CCL16 rapidly neutralize a TSA
challenge that would otherwise be lethal. Other cytokines
only delay tumour growth (IFN-γ) or have no inhibitory effect
(IL-5 and IL-6) [10,11,13]. Similarly, protective inflammatory
reactions are triggered through repeated local injection of
recombinant cytokines [8,16,17].
Inflammation modulates neu (ERBB2, or
HER-2/neu) driven mammary carcinogenesis
The time frame obviously differentiates acute inflammation
from the chronic reactions that set the stage for initiation of
carcinogenesis and its progression. Because chronic inflam-
mation is a long-lasting response to an enduring invasion, it
can persist for a significant period of time in the life of the
individual. Prolonged release of a mixture of highly reactive
oxidants secreted by infiltrating leucocytes may damage the
genomes of nearby cells and increase their rate of mutation
[18]. In addition to this direct oncogenic effect, a chronically
inflamed microenvironment possesses many mechanisms
with which to promote progression of a preneoplastic lesion,
as described elsewhere in this series of review articles.
Cancer-prone transgenic mice provide models of autoch-
thonous tumour formation. We conducted a microarray
gene expression analysis to determine how proinflammatory
genes are switched on during the stepwise progression of
neu oncogene driven mammary carcinogenesis in BALB/c
mice.
BALB/c mice transgenic for the transforming rat neu664V-E
oncogene under the transcriptional control of the mouse
mammary tumour virus promoter (BALB-neuT664V-E mice) are
genetically predestined to develop one of the most aggres-
sive forms of mammary carcinogenesis, with penetrance of
all of their mammary glands. Starting from the week 3 or 4 of
age, the protein product of the neu oncogene (p185neu) is
diffusely over-expressed in the terminal buds of mammary
glands of virgin mice. The over-expressing cells form foci of
atypical hyperplasia. At around 8 weeks of age, these
enlarge to in situ carcinomas that progress to invasive
cancer between weeks 17 and 22. At around weeks 17 to
18 one or more tumours are palpable in the mammary pad of
all mice, and at around week 33 a tumour is palpable in each
of the 10 mammary glands [19]. The p185neu over-
expression in the thymus and mammary gland has a marked
effect on the T-cell repertoire of these mice, and CD8+ T-cell
clones reacting with dominant p185neu epitopes are deleted
[20]. Moreover, during progression of the mammary lesions,
both suppressor CD4+ CD25+ FOXP3+ GITR+ Treg cells
[21] and CD11b+ Gr1+ immature myeloid cells [22] expand.
This mammary carcinogenesis appears to be driven in a
straightforward manner by the transgenic neu oncogene,
which provides abnormal growth signals and inhibits cell
death pathways [23].
Figure 1
Most significant Ingenuity functional classes found to be enriched in GATMs. GATM, gene associated with mammary tumour microenvironment.Page 3 of 9
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Because the genetic alteration is the driving force of tumor
development in the BALB-neuT664V-E model, and because the
mammary gland is not commonly susceptible to chronic
inflammation, interactions between the incipient tumour and
its inflammatory microenvironment presumably do not play a
major role. In contrast, progression of this devastating form of
carcinogenesis is markedly modulated by the inflammatory
microenvironment. The inflammation-related reaction elicited
by repeated injections of recombinant IL-12 during the early
stages of carcinogenesis results in restricted and delayed
tumour formation [24], mostly resulting from the ability of
IL-12 to trigger innate immunity reaction mechanisms and
induce downstream factors that inhibit the angiogenic switch,
which promotes progression from in situ to invasive cancer
Available online http://breast-cancer-research.com/content/9/4/211
Table 1
Functional network generated by Ingenuity knowledge database analysis
Hub gene Score GATMs Top functions
TNF↑ 34 35 Lipid metabolism, small molecule biochemistry, cell death
IFNG↑ 34 35 Lipid metabolism, molecular transport, small molecule biochemistry
IL1B↑ 34 35 Immune response, cellular movement, haematological system development and function
MYC↑ 34 35 Cell cycle, cellular movement, cancer
CCL2↑, KDR↓, VEGF↓ 34 35 Cellular movement, cancer, tumour morphology
SRC↑ 34 35 Haematological system development and function, immune and lymphatic system 
development and function, tissue morphology
BCL2↑ 34 35 Cancer, cell death, cell morphology
AGT↓ 34 35 Cell-to-cell signalling and interaction, haematological system development and function, 
immune and lymphatic system development and function
TIMP1↑, EDN1↓ 34 35 Cancer, cellular movement, cellular development
LEP↓ 34 35 Lipid metabolism, molecular transport, small molecule biochemistry
AR↓ 34 35 Cellular growth and proliferation, gene expression, cellular development
IGF2↓, ERBB3↑ 34 35 DNA replication, recombination, and repair, cancer, cell cycle
HOXA9↓, CDH1↑ 34 35 Cellular growth and proliferation, cell death, cancer
ARNT2↑, ZAP70↑ 34 35 Cellular growth and proliferation, haematological system development and function, immune 
response
PPARA↓, IL6, SERBF1 15 24 Lipid metabolism, small molecule biochemistry, molecular transport
CDC42, RAC1 13 22 Cell signalling, free radical scavenging, nucleic acid metabolism
ERBB2↑ 12 17 Cancer, tumour morphology, cell cycle
FN1 12 21 Cell-to-cell signalling and interaction, cellular movement, reproductive system development 
and function
FOS 12 21 Gene expression, cell cycle, haematological system development and function
IGF1, CCND1, BMP2 12 21 Cellular growth and proliferation, connective tissue development and function, skeletal and 
muscular system development and function
IL4 12 21 Cellular assembly and organization, cell cycle, DNA replication, recombination, and repair
NFYB 11 16 Cancer, cell cycle, cellular assembly and organization
IL13, MAPK8, NFKB1 11 20 Haematological system development and function, immune and lymphatic system 
development and function, tissue morphology
STAT3, INSR, PTPN 11 20 Cellular growth and proliferation, haematological system development and function, immune 
response
NFKBIA, CD40LG, HGF 11 20 Cell death, cellular movement, haematological system development and function
KRAS, CDKN1A 10 19 Cellular growth and proliferation, cell signalling, cancer
TNF↑ 10 19 Carbohydrate metabolism, molecular transport, small molecule biochemistry
Out of the 55 available networks, only those containing at least 10 genes associated with mammary tumour microenvironment (GATMs) are shown.
↑ and ↓ indicate gene expression increasing and decreasing on passing from the pre-neoplastic condition to neoplasia, respectively.[25]. Conversely, a marked modulation of the progression of
neu carcinogenesis is evident in mice in which the gene
encoding IFN-γ [26] or that encoding monocyte chemo-
attractant protein (MCP)-1/CCL2 [27] has been knocked out.
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Figure 3
Network of functional association between IFN-γ gene and other
GATMs generated by Ingenuity database analysis. ADIPOQ, CCL22,
IFNG, IL1B, PPARA, RXRG, MSR1, GAD1 and TAP1 are genes
associated with proliferation, whereas USP18 and CDH13 are genes
linked to growth. ASS, DUSP5, ADCY5 and UBD are genes
associated with apoptosis/survival. CXCR6, CXCL16 and CNR2 are
genes associated with chemotaxis/trafficking; KLRK1 and HCST are
associated with cytolysis/cytotoxicity; and RARRES1 and CD36 are
linked to migration. All of the other genes have unknown cell functions.
Genes are shown by their symbols. GATM, gene associated with
mammary tumour microenvironment; IFN, interferon.
Figure 2
Network of functional association between TNF gene and other
GATMs generated by Ingenuity database analysis. RAET1B, KLRD1
and KLRK1 are genes associated with cytotoxicity; TNFRSF21 and
AATK are genes involved in apoptosis. LITAF, AK2 and KLRC2 are
genes associated with proliferation regulation. PLA2G7 is a gene
associated with inflammatory response. All of the other genes have
unknown cell functions. Genes are shown by their symbols [44]. The
nodes represent the genes and the edges reflect direct links or
connections between them. GATM, gene associated with mammary
tumour microenvironment; TNF, tumour necrosis factor.
Figure 5
Network of functional association between CCL2 gene and other
GATMs generated by Ingenuity database analysis. F3, F2R, F12, F10
and KNG1 are part of the complement and coagulation cascades.
MMP12 encodes a matrix metalloproteinase involved in tissue
remodelling. HBEGF and PGF encode growth factors. Associations
with VEGF and KDR have been omitted for the sake of legibility.
Genes are shown by their symbols. CCL, CC chemokine ligand;
GATM, gene associated with mammary tumour microenvironment.
Figure 4
Network of functional relationships between IL-1β gene and other
GATMs generated by Ingenuity database analysis. AIF1, CCL4,
CCL5, CCL7, CXCL6, IL1B, NFKBIZ and PIGR are associated with
the inflammatory response. All of the other genes have unknown cell
functions. Genes are shown by their symbols. GATM, gene associated
with mammary tumour microenvironment; IL, interleukin.Inflammatory gene expression during neu
carcinogenesis
We have used DNA microarray technology to compare
patterns of transcription in 2-week pregnant wild-type
BALB/c mice with those in the mammary glands of BALB-
neuT664V-E mice during progression of neu carcinogenesis
[28,29]. We also characterized the transcription profile in the
gland when carcinogenesis is halted by immune mechanisms
triggered by cell [30] and DNA-based anti-neu vaccines
[28,31]. Meta-analysis of these transcription profiles [32] has
provided suggestions regarding possible new onco-antigens
for use in anti-tumour vaccines.
A recent transcription profiling study using full, genome-wide
mouse arrays was run to identify changes in transcription in
BALB-neuT664V-E mammary glands progressing from atypical
hyperplasia and in situ carcinomas (10- to 15-week-old mice)
to invasive cancer (19- to 22-week-old mice) (unpublished
data; the microarray dataset has been released, GSE7395,
on the GEO database, www.ncbi.nlm.nih.gov/geo). The total
RNAs extracted from mammary glands were analyzed using
Mouse Genome Survey Microarrays (Applied Biosystems,
Foster City, CA, USA). Identification of differentially expres-
sed genes associated with the transition from the pre-
neoplastic state to neoplasia was done by means of a linear
modelling approach [33]. An empirical Bayesian method [34]
was used to assess differential expression, along with false
discovery rate correction of the P value [35] to moderate the
standard errors of the estimated log-fold changes. We
identified 2,758 differentially expressed probes (2,651
transcripts) by applying a false discovery rate of 0.05,
associated with an absolute log2 (fold change) threshold of 1.
These differentially expressed genes represent the element of
the mammary gland transcriptome whose expression changes
as the tumour microenvironment evolves and the tumour mass
increases. Therefore, these transcripts are defined as genes
associated with mammary tumour microenvironment (GATMs).
The Ingenuity Pathways Knowledge Base [36] is currently the
world’s largest database of knowledge on biological
networks, with annotation curated by experts. We exploited
this database to define the presence of functional
associations within the GATMs and to identify differences
between the ontological gene classes [37] that were
enriched among the upregulated and downregulated genes
(Figure 1). This ontological gene classification provides the
controlled vocabulary to describe gene and gene product
attributes. The principal Ingenuity ontological classes found
to be enriched in BALB-neuT664V-E GATM sets are those
related to cellular movement and cellular growth and
proliferation. However, among the other significantly enriched
groups were genes belonging to the classes inflammatory
diseases, haematological system development and function,
and immune and lymphatic system development and function.
Available online http://breast-cancer-research.com/content/9/4/211
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Figure 6
Clustering of expression of genes associated to inflammation. Shown is hierarchical clustering of gene-centred expression of the 65 genes present
in the IFN-γ, TNF, IL-1β and MCP-1/CCL2 gene functional association networks. Samples from the dataset, presented by Chin and coworkers
[38], cluster in three groups (A, B and C) if the expression levels of the proinflammatory genes are used. CCL, CC chemokine ligand; IFN,
interferon; IL, interleukin; MCP, monocyte chemoattractant protein; TNF, tumour necrosis factor.This highlights the collaboration between transformed cells
and body defence systems during initial tumour development.
Furthermore, we generated significant functional association
networks [37] encompassing GATMs (Table 1). These are
graphical descriptions of literature associations identified by
the Ingenuity knowledge database, in which gene products
are linked if some kind of experimentally measured associa-
tion has been reported. The 14 most significant gene
networks, each composed of 35 GATMs (nodes), are
characterized by the presence of one hub gene (the highest
connected node), which is the main player in the biological
events that connect the GATMs. Remarkably, four of these
14 networks are highly associated with the inflammatory
response: TNF (Figure 2), IFN-γ (Figure 3), IL-1β (Figure 4)
and MCP-1/CCL2 (Figure 5).
During neu carcinogenesis, these four functional association
networks, centred on genes that encode proinflammatory
molecules, can be defined. To ensure that these networks
were not an artefact of the experimental model, we assessed
their expression in breast cancer specimens in the light of
recently published data exploring associations between
recurrent copy number abnormalities, gene expression, and
clinical outcomes in a set of aggressively treated early-stage
breast tumours [38].
The presence of GATMs associated with TNF, IL-1β, IFN-γ,
and MCP-1/CCL2 hub genes, and characterized by human
orthologs (a total of 77 genes), was sought in the dataset
reported by Chin and coworkers [38]. This is one of the
largest collections of breast cancer samples (n = 118)
analyzed by microarray and for which the clinical outcome is
known. The study showed that the accuracy with which early-
stage breast cancer patients can be stratified according to
outcome can be improved by combining analyses of gene
expression and genome copy number.
We identified 65 out of 77 GATMs. Hierarchical clustering
of their expression profile (a method for dividing a dataset
into subsets whose individual data ideally share some
common traits [37]) was used to group the sample reported
by Chin and coworkers into three subsets (Figure 6). This
clustering was based on a proinflammatory gene signature,
and it revealed different types or degrees of leucocyte
infiltration. This suggests that proinflammatory activation in
the mammary glands of BALB-neuT664V-E mice reflects a
general pattern of human breast cancer. Only a limited
overlap between the A group and a subset of samples
characterized by negative oestrogen receptor status was
observed (data not shown). This is not surprising, because
our study addressed BALB-neuT664V-E carcinogenesis sequen-
tially, whereas only full-blown cancers were considered in the
report by Chin and coworkers [38]. Moreover, sampling bias
in the human setting may mask any correlation with clinical
outcome.
A complementary dataset that could corroborate our obser-
vations is that report by Neve and coworkers [39]. Those
investigators found that the recurrent genomic and trans-
criptional characteristics of a large set of breast cancer cell
lines mirrored those of primary breast tumours, although
some significant differences were documented.
The work reported by Chin [38] and Neve [39] and their
colleagues offers a unique opportunity to discriminate
between transcripts that belong to the tumour micro-
environment and those associated with tumour cells. Taking
advantage of these transcriptional profiles [38,39] and
specific data mining techniques [40], one can determine
whether a set of genes shares little expression similarity
between tumour specimens and cell lines. This would
suggest that their expression is linked to cell infiltrates and
does not belong to tumour cells. Such a scenario was
actually observed for the set of proinflammatory genes that
we identified in BALB-neuT664V-E mice because of the
absence of correlation [40] between gene expression
observed in tumour specimens [38] and in tumour cell lines
[39] (Figure 7).
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Figure 7
Scatterplot of pair-wise correlation comparison within the probe sets in
the two datasets. Integrative correlation coefficient [40] was used to
quantify the extent of the similarity between the tumour specimens and
breast cancer cell line transcription profiles. All pair-wise correlations
(Pearson correlation coefficient) of gene expression across samples
within individual projects were calculated, and the reproducibility of the
results was defined without relying on direct comparison of expression
across platforms.It should nonetheless be noted that the gene encoding MCP-1/
CCL2 is the only one of the four hub genes (those encoding
IFN-γ, TNF, IL-1β and MCP-1/CCL2) that constantly exhibit
relatively high levels of expression (Figure 8).
Conclusion
The  neu oncogene is the central driving force of the
mammary cancer that inexorably kills all female BALB-
neuT664V-E mice. Even so, the timeframe within which neu
carcinomas appear and progress is modulated by the pro-
inflammatory components of the reactive stroma that
surrounds the cancer lesions.
Our transcription profiling search for modulation of GATMs
during the progression of neu mammary lesions in BALB-
neuT664V-E mice generated a large body of data. The Ingenuity
knowledge database was used to identify four functional
association networks whose hub genes are directly linked to
inflammation (namely, the genes that encode IFN-γ, TNF,
IL-1β and MCP-1/CCL2). Data from such analyses clearly
show that the progression of neu-driven autochthonous
carcinogenesis is directly associated with increased
expression of these four hub GATMs. These data were from a
representative but artificial experimental model. However, an
in silico meta-analysis in a human breast cancer dataset
suggests that proinflammatory activation in the mammary
glands of BALB-neuT664V-E mice reflects the general pattern
of human breast cancer.
However, the way in which the proinflammatory cytokines
encoded by these genes affect the progression of neu
carcinogenesis is neither simple nor unequivocal. Different
amounts of the same cytokine in the tumour microenviron-
ment may have different influence, whereas the significance
of this influence can fluctuate during the distinct stages of
cancer progression. For instance, increased expression of
IFN-γ in the tumour microenvironment during neu  tumour
progression does not appear to favour tumour expansion but
plays a major inhibitory role. In BALB-neuT664V-E IFN-γ
knockout mice, absence of IFN-γ leads to accelerated
progression of neu carcinogenesis [26]. Work in progress
suggests that this more rapid progression is associated with
a major increase in tumoural neoangiogenesis (Iezzi M,
unpublished data). Indeed, it is well known that IFN-γ, as well
as the downstream factors that it induces, have marked anti-
angiogenic activity that naturally restricts tumour neoangio-
genesis and hampers tumour growth [41].
Moreover, our work on administration of recombinant mouse
IL-12 shows that IL-12 mediated inhibition of neu carcino-
genesis relies on production of IFN-γ in the tumour micro-
environment [41]. In BALB-neuT664V-E IFN-γ knockout mice,
Available online http://breast-cancer-research.com/content/9/4/211
Page 7 of 9
(page number not for citation purposes)
Figure 8
Box-plot of the expression level distributions of the 65 GATMs presented by Chin and coworkers. The IFN-γ, TNF, IL-1β and MCP-1/CCL2 hub
genes are shown in grey. The inset figure shows their expression levels within the intensity distribution of tumour dataset presented by Chin and
coworkers [38]. CCL, CC chemokine ligand; GATM, gene associated with mammary tumour microenvironment; IFN, interferon; IL, interleukin;
MCP, monocyte chemoattractant protein; TNF, tumour necrosis factor.IL-12 no longer impairs tumour growth [25]. We have also
found that the ability of IL-12 induced IFN-γ to inhibit the
progression of neu carcinogenesis is related to tumour stage.
It is very marked during the tumour-induced angiogenic
switch that accompanies the passage from an in situ lesion
to invasive cancer. The newly formed capillary sprouts that
characterize the early events in the angiogenic switch are
sensitive to the inhibitory activity of IFN-γ, whereas this
activity is nearly absent in the stages that precede and follow
the switch [24].
Our data show that the expression of the gene that encodes
the MCP-1/CCL2 chemokine increases as neu carcino-
genesis progresses. The presence of this chemokine in the
reactive stroma around the tumour appears to be directly
associated with enhanced progression, because in BALB-
neuT664V-E MCP-1/CCL2 knockout mice progression is
slower and mice survive longer [27].
The influence of different levels of TNF and IL-1β has not
been assessed in BALB-neuT664V-E mice. However, data from
other experimental systems suggest that local increases in
these factors may favour cancer progression. Skin
carcinogenesis is dramatically impaired in TNF-α knockout
mice [42]. In various experimental models, IL-1β appears to
increase tumour invasiveness and metastasis [43].
In conclusion, our Ingenuity analysis identifies four genes that
encode inflammatory cytokines whose increased expression
in the tumour microenvironment is naturally associated with
mammary cancer progression. Much greater concentrations
of the very same cytokines, artificially reached in the tumour
microenvironment either through their local injection or from
cells engineered to release them, lead to both tumour
rejection and induction of long-lasting tumour-specific immune
memory [10].
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